These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 18676330

  • 1. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ, Hsu A.
    Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
    [Abstract] [Full Text] [Related]

  • 2. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J.
    Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [Abstract] [Full Text] [Related]

  • 3. Temsirolimus in renal cell carcinoma.
    Otto T, Eimer C, Gerullis H.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [Abstract] [Full Text] [Related]

  • 4. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
    Kapoor A, Figlin RA.
    Cancer; 2009 Aug 15; 115(16):3618-30. PubMed ID: 19479976
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA.
    Nat Clin Pract Oncol; 2008 Oct 15; 5(10):601-9. PubMed ID: 18607393
    [Abstract] [Full Text] [Related]

  • 6. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial.
    N Engl J Med; 2007 May 31; 356(22):2271-81. PubMed ID: 17538086
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
    Wood LS, Manchen B.
    Clin J Oncol Nurs; 2007 Oct 31; 11(5):649-56. PubMed ID: 17962173
    [Abstract] [Full Text] [Related]

  • 8. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
    Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP.
    J Clin Oncol; 2007 Sep 01; 25(25):3958-64. PubMed ID: 17761980
    [Abstract] [Full Text] [Related]

  • 9. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
    Boni JP, Hug B, Leister C, Sonnichsen D.
    Semin Oncol; 2009 Dec 01; 36 Suppl 3():S18-25. PubMed ID: 19963096
    [Abstract] [Full Text] [Related]

  • 10. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
    Fujisaka Y, Yamada Y, Yamamoto N, Horiike A, Tamura T.
    Jpn J Clin Oncol; 2010 Aug 01; 40(8):732-8. PubMed ID: 20430774
    [Abstract] [Full Text] [Related]

  • 11. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
    Bhatia S, Thompson JA.
    Adv Ther; 2009 Jan 01; 26(1):55-67. PubMed ID: 19172239
    [Abstract] [Full Text] [Related]

  • 12. Molecule of the month. Temsirolimus.
    Drug News Perspect; 2007 Jan 01; 20(6):406. PubMed ID: 17925894
    [No Abstract] [Full Text] [Related]

  • 13. Targeting mTOR in renal cell carcinoma.
    Hudes GR.
    Cancer; 2009 May 15; 115(10 Suppl):2313-20. PubMed ID: 19402072
    [Abstract] [Full Text] [Related]

  • 14. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
    Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML.
    J Clin Oncol; 2004 Mar 01; 22(5):909-18. PubMed ID: 14990647
    [Abstract] [Full Text] [Related]

  • 15. New treatment approaches in renal cell carcinoma.
    Facchini G, Perri F, Caraglia M, Pisano C, Striano S, Marra L, Fiore F, Aprea P, Pignata S, Iaffaioli RV.
    Anticancer Drugs; 2009 Nov 01; 20(10):893-900. PubMed ID: 19752718
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
    Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L.
    J Clin Oncol; 2005 Aug 10; 23(23):5314-22. PubMed ID: 15955899
    [Abstract] [Full Text] [Related]

  • 17. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
    Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B.
    J Clin Oncol; 2009 Aug 10; 27(23):3822-9. PubMed ID: 19581539
    [Abstract] [Full Text] [Related]

  • 18. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY, Grossman AB, Bukowski RM.
    Adv Ther; 2010 Aug 10; 27(8):495-511. PubMed ID: 20623346
    [Abstract] [Full Text] [Related]

  • 19. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
    Shuuin T, Karashima H.
    Gan To Kagaku Ryoho; 2009 Jul 10; 36(7):1076-9. PubMed ID: 19620795
    [Abstract] [Full Text] [Related]

  • 20. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
    Ravaud A, Bernhard JC, Gross-Goupil M, Digue L, Ferriere JM.
    Bull Cancer; 2010 Jul 10; 97():45-51. PubMed ID: 20418203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.